Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results
Vipul Jairath, F Magro, M Protic, Gert De Hertogh et autres
0 citationsJournal of Crohn s and Colitis
Shalini Iyengar
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
7Publications signalées
327Citations signalées
0Affiliations récentes
Domaines associés
SARS-CoV-2 and COVID-19 ResearchInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies
Publications récentes
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
Akshay S. Desai, Adam Karns, Jolita Badarienė, Ahmad Aswad et autres
35 citationsJAMA
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Marc Ferrante, Geert D’Haens, Vipul Jairath, Minhu Chen et autres
109 citationsThe Lancet
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight
Olivia Bird, Eva Galiza, D. N. Baxter, Marta Boffito et autres
6 citationsEpidemiology and Infection
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Paul T. Heath, Eva Galiza, D. N. Baxter, Marta Boffito et autres
74 citationsClinical Infectious Diseases
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
Paul T. Heath, Eva Galiza, D. N. Baxter, Marta Boffito et autres
21 citationsmedRxiv
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway et autres
82 citationsUCL Discovery (University College London)
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.